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CHAPTER - I 
INTRODUCTION 
1.1.Medicinal chemistry 
The practice of medicinal chemistry is devoted to the discovery and development 
of new agent for treating diseases. It involves, structure modification for 
optimization of their activity and other physical properties and total and semi- 
synthetic for a thorough scrutiny of structure activity relationship. The rapid process 
in molecular biology, computational chemistry, combinatorial chemistry and high 
throughput screening technologies has begun to reshape the pharmaceutical Industry. 
Most of the activity in this    discipline is directed to new natural or synthetic 
organic compound. The process of establishing a new drug is complex process which 
involving the talent of people from the variety of discipline including chemistry, 
biochemistry, physiology, pharmacology, pharmaceutics, and medicines. The 
medicinal chemistry is concerned mainly with the organic, Analytical, biological, 
chemical, aspects of this process1-5. 
1.2.Drug Discovery 
Discovery is the identification of novel active compounds, often called "hits", 
which are typically found by screening many compounds (compound library) for the 
desired biological properties. While a number of approaches toward the identification of 
hits exist, the most successful of techniques relies on chemical and biological intuition 
developed through years of rigorous chemical-biological training. The process of 
optimizing the lead molecule into a potent drug is usually the longest and most 
expensive stage in the drug discovery process6. 
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humans. Obviously such clinical trials cannot be used for initial drug development, 
which means that a potential target must undergo a validation process - its role in 
disease must be clearly defined before drugs are sought that act against it, or before it is 
used to screen large numbers of compounds for drug activity7. 
The validation of a molecular target in vitro usually precedes the validation of 
the therapeutic concept in vivo; together this defines its clinical potential. Validation 
involves studies in intact animals or disease-related cell-based models that can provide 
information about the integrative response of an organism to 
a pharmacological intervention and thereby help to predict the possible profile of new 
drugs in patients. 
Target discovered computationally, must be experimentally validated. It can be done by  
¾ Knock out or knock in of the gene of interest. 
¾ Use of RNA antisense technology to validate the gene. 
¾ Combined analysis of miRNAs and their target mRNAs. 
¾ Target gene prediction based on expert bioinformatics. 
¾ Pathway specific gene expression profiling. 
¾ Comprehensive statistical analysis of regulated networks. 
1.2.4. Lead Identification 
  After a target has been identified and validated, chemical leads (of low or 
medium potency) must be identified. Leads can be an analog of any natural ligand or it 
may be design using de novo methods. Lead identification starts with the design and 
development of a suitable assay to monitor the target under study. Subsequently, high-
throughput screening (HTS) exposes the target to a large number of chemical 
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compounds (typically in the order of 105) that increasingly come from high-speed 
parallel and combinatorial synthesis. 
        Virtual screening and combinatorial chemistry plays an important role in 
generating leads. 
 Two methods are used for searching database of compounds against protein 
structures as follows 
• Pharmacophore based method which describes the functionally important 
sites in a ligand binding site. These sites can be determined by using 
software like GRID.7 
• Docking based method which involves fitting a small molecular structure to 
a protein binding site and calculating the binding energy and other 
functions8-11. 
1.2.5. Lead optimization 
 Lead optimization is a complex, non-linear process. During this stage of drug 
discovery, the chemical structure of a confirmed hit is refined to improve its drug 
characteristics with the goal of producing a preclinical drug candidate. Lead 
optimization often involves a series of standard assays to evaluate toxicity, including 
P450 inhibition, cytotoxicity assays, and hERG testing. Toxicity in these relatively 
simple in vitro assays flags hits or leads that could have potential safety concerns. 
  Lead optimization employs a combination of empirical, combinatorial, and 
rational approaches that optimize leads through a continuous, multi-step process based 
on knowledge gained at each stage. Typically, one or more confirmed hits are evaluated 
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in secondary assays, and a set of related compounds, called analogs, are synthesized 
and screened. 
  The lead optimization process is highly iterative. Leads are assessed in 
pharmacological assays for their "druglikeness." Medicinal chemists change the lead 
molecules based on these results in order to optimize pharmacological properties such 
as bioavailability or stability. At that point the new analogs feed back into the screening 
hierarchy for the determination of potency, selectivity, and MOA. These data then feed 
into the next optimization cycle. The lead optimization process continues for as long as 
it takes to achieve a defined drug profile that warrants testing of the new drug in 
humans. 
1.3.Quantitative Structure Activity Relationship12-15 
   Quantitative structure-activity relationships (QSAR) represent an attempt to 
correlate structural or property descriptors of compounds with activities. These 
physicochemical descriptors, which include parameters to account for hydrophobicity, 
topology, electronic properties, and steric effects, are determined empirically or, more 
recently, by computational methods. Activities used in QSAR include chemical 
measurements and biological assays. Quantitative structure-activity relationships have 
long been considered a vital component of drug discovery and development, providing 
insight into the role of molecular properties in the biological activity of similar and 
unrelated compounds. 
 QSAR (quantitative structure-activity relationships) includes all statistical 
methods, by which biological activities (most often expressed by logarithms of 
equipotent molar activities) are related with structural elements (Free Wilson analysis), 
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physicochemical properties (Hansch analysis), or fields (3D QSAR). The CoMFA 
analyses provided a number of insights into the mechanism of agonist binding. 
 
 Classical QSAR analyses (Hansch and Free Wilson analyses) consider only 
2D structures. Their main field of application is in substituent variation of a 
common scaffold. 
 3D-QSAR analysis (CoMFA) has a much broader scope. It starts from 3D 
structures and correlates biological activities with 3D-property fields. 3D QSAR 
is a variant of the classical QSAR method (sometimes referred to as 2D 
QSAR), in which the descriptors are based on the 3D structure of the 
compounds instead of macroproperties like weight and volume. 
A QSAR generally takes the form of a linear equation: 
 
  
 Where the parameters P1 through Pn are computed for each molecule in the 
series and the coefficients c1 through cn are calculated by fitting variations in the 
parameters and the biological activity. 
1.4. Heterocyclic chemistry 
Heterocyclic chemistry is the chemistry branch dealing exclusively with 
synthesis, properties and application of heterocyclic compound. Heterocyclic compound 
is an organic compound that contains a ring structure containing atom in addition to 
carbon such as sulfur, oxygen or nitrogen as part of the ring. They may be either simple 
aromatic ring or non aromatic rings. Nitrogen containing heterocyclic compounds is the 
Biological Activity = Const + (c1×P1) + (c2×P2) + (c3×P3) + ... 
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key building blocks used to develop compounds of biological and medicinal interest; a 
heterocyclic compound is one which possesses a cyclic structure with at least two 
different kinds of hetero atoms in the ring. Nitrogen, oxygen, and sulphur are the most 
common heteroatom. 
The chemistry and biological study of heterocyclic compounds has been an 
interesting field for a long time in medicinal chemistry. Heterocycles containing 
thiazole, quinoline, benzoxazole, benzothiazole and benzimidazole moiety, to identify 
new candidates that may be value in designing new, potent, selective and less toxic 
agents, being a heterocyclic compound, thiazole and thiadiazole finds use in research as 
a starting material for the synthesis of larger, usually bioactive structures. In recent year 
heterocyclic compounds analogues and derivatives have attracted strong interest due to 
their useful biological and pharmacological properties. The small and simple thiazole 
nucleus is present in compounds involved in research aimed at evaluating new products 
that possess biological activities. 
Combination of two active pharmacophores into one molecule is one of the 
novel drug designing techniques used in drug discovery programme. In this 
communication, we report our early attempts to design and evaluate some of the novel 
molecules for antimicrobial, and anti fungal activities. With the recent increased interest 
in the above area. Search for such potential drugs has been in the forefront of 
pharmaceutical sciences. In this series, we have combined two active pharmacophores, 
namely antimicrobial drugs like thiazole-thiadiazole derivatives, which is under clinical 
practice for the treatment on microbial and fungicidal diseases. This exhibits interesting 
antimicrobial activity along with an anti fungal activity16-19. 
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1.5.Naphthoquinone 
Naphthoquinone
O
O
 
Quinones are widely-distributed aromatic compounds present throughout nature 
and can be found in several families of plants, as well as isolated from fungi, algae and 
bacteria. Quinones are classified into benzoquinones, anthraquinones and 
naphthoquinones according to their chemical structures. Naphthoquinones are 
structurally related to naphthalene and are characterized by their two carbonyl groups in 
the 1, 4 position and it is named as 1, 4-naphthoquinones. Carbonyl groups may also be 
present at the 1, 2 position with minor case. Naphthoquinones are present in three 
tautomeric forms shown in figure 1.2. The 1,4-naphthoquinone structure is the most 
stable form followed by 1, 2-naphthoquinone and 1,2,4-naphthotrione20. The 1, 2, 4-
naphthotrione is the least stable but is probably in equilibrium in solution with the other 
two tautomeric forms. This stability is due to cancelation of dipolar moments of 
carbonyl groups, in combination with intra molecular hydrogen bonds in the 1,4 isomer. 
2- Hydroxy 1,4 naphthoquinone
O
O
OH
4- Hydroxy 1,2 naphthoquinone
O
O
OH
1,2,4 naphthotrione
O
O
O
 
Figure 1.2 Tautomeric forms Naphthoquinone 
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1.5.1. Natural occurrence and pharmacological activity of Naphthoquinone and its 
derivatives 
1, 4-naphthoquinones are widely distributed in nature, especially in several 
families of higher plants (Plumbaginaceae, Juglandaceae, Ebenaceae, Boraginaceae, 
Dioncophyllaceae, Ancistrocladaceae, Iridaceae, Verbenaceae, Scrophulariaceae, 
Avicenniaceae, Balsaminceae, Bignoniaceae, Gentianaceae, Droseraceae, 
Nepenthaceae, Lythraceae and Euphorbiaceae) besides also being present in algae, 
fungi, some animals and as products of metabolism in some bacteria21.  
Naphthoquinones and their derivatives contain electrophilic α,β-unsaturated 
carbonyl compounds. Due to this it has the ability to form covalent with nucleophilic 
groups present in biological molecules and produce better pharmacological action. 
Naphthoquinones may act as electrophiles, by interacting with nucleophilic functional 
group present in biological molecules in an arylation reaction.  The discovery of vitamin 
K1 and vitamin K2 marked a new era in the development of 1,4-naphthoquinones as 
therapeutic agents. Both these vitamins are antihemorrhagic and are concerned with the 
enzymes involved in blood clotting. Quinones are present in many drugs such as 
anthracyclines, daunorubicin, doxorubicin, mitomycin, mitoxantrones and saintopin, 
which are used clinically in the therapy of solid cancers22. 1,4-Naphthoquinone 
derivatives also elicit several interesting and various biological responses such as 
antibacterial15, antifungal, anti-inflammatory23, antithrombotic24, antiplatelet25,26, 
antiviral 27, anticancer28, antiallergic29, apoptosis30, lipoxygenase31, radical scavenging32  
and anti-ringworm activities. 1, 4-naphthoquinone derivatives have been proved to be a 
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human DNA topoisomerase I and II inhibitor. The various drugs contains 
Naphthoquinone nucleus, some of its shown in figure 1.3 
 
Figure 1.3. Various drugs contains Naphthoquinone nucleus 
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1.5.2. Napthoquinone derivatives as potent anti-cancer agents 
The quinone scaffold is presented in many currently used anticancer drugs33. 
Particularly, 1,4-naphthoquinones are active quinone derivatives that are widely used as 
raw materials in pharmaceuticals and agrochemicals industries. A diverse array of 
bioactivities has been reported for 1,4-naphthoquinone derivatives to exert anticancer , 
antimicrobial, antifungal, antiviral, radical scavenging, antiplatelet  and trypanocidal34 
activities. 1,4-Naphthoquinone contains two ketone groups as a crucial chromophore 
that accounts for its bioactivities owing to their ability to accept electrons. Structure 
activity relationship study indicated that cytotoxic activity of 1,4-naphthoquinones are 
closely related with their electron accepting capability, which gives rise to reactive 
oxygen species (ROS) production leading to DNA damage and cell death35. 
Furthermore, enhanced antimicrobial activity was reported in amino derivatives of 1,4- 
naphthoquinone. The findings indicated that the nitrogen atom of the amino substituent 
could improve the redox potential of the quinone system. In addition, insertion of a 
chlorine substituent into the amino derivative of 1,4-naphthoquinone nucleus was found 
to improve the redox potential of compounds while not significantly affecting their 
hydrophobicities . 
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Figure 1.4. Possible anticancer effect of 1,4-quinone 
 
1.5.3. Napthoquinone derivatives as Topoisomerase I inhibitors 
DNA topoisomerase I releases the supercoiling and torsional tension of DNA 
introduced during the DNA replication and transcription by transiently cleaving and 
rejoining one strand of the DNA duplex. It introduces a single-strand break via 
transesterification at a target site in duplex DNA. The scissile phosphodiester is 
attacked by the catalytic tyrosine of the enzyme, resulting in the formation of a DNA-
(3'- phosphotyrosyl)-enzyme intermediate and the expulsion of a 5'-OH DNA strand. 
The free DNA strand then undergoes passage around the unbroken strand thus removing 
Introduction 
 
JKKN College of Pharmacy, Kumarapalayam.  Page 27 
 
DNA supercoils. Finally, in the relegation step, the DNA 5'-OH attacks the covalent 
intermediate to expel the active-site tyrosine and restore the DNA phosphodiester 
backbone. The topoisomerase enzymes have been researched as targets for the 
generation of new cancer treatments because when they are inhibited in a cell, the result 
is that the cell dies. The proven ability of topoisomerase I to efficiently regulate 
topology of DNA has prompted many pharmaceutical groups to pursue inhibitors of 
topoisomerase I for the potential treatment of cancer. To name some recognizable 
drugs, the topoisomerase I inhibitors are Camptothecin and its derivatives. 
Camptothecins are among the most effective anticancer agents recently introduced into 
clinical practice. In this regard, the Camptothecin derivative Topotecan (Hycamtin) is 
approved by the  U.S. FDA for the treatment of ovarian and lung cancer36-38. 
Another class of topoisomerase I inhibitors are Napthoquinones. 
Naphthoquinone is a class of natural phenols based on the C6-C4 skeleton. 1, 4- 
Naphthoquinone can be viewed as derivatives of naphthalene through the replacement 
of two hydrogen atoms by two ketone groups. . Naphthoquinone derivatives have 
significant pharmacological properties. They are cytotoxic; they have significant 
antibacterial, antifungal, antiviral, insecticidal, antiinflammatory, and antipyretic 
properties 39.  
Nowadays, their important pharmacological activity is also attributed to the 
inhibition of special proteins, such as: bacterial topoisomerase II-DNA gyrase- 
(antibacterial), mammalian topoisomerases I and II (antitumor) and HIV-1 integrase and 
proteinase (antiviral). Many derivatives of Naphthoquinones have been reported to 
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show anti topoisomerase 1 activity. They have been proved to be a human DNA 
topoisomerase I inhibitor.  
Literature survey shows that, various scaffolds specific 2D QSAR models for 
Naphthoquinone derivatives have been generated to understand the structure activity 
relationship of Naphthoquinone. However the exact mechanism of naphthoquinones 
binding to topoisomerase I is still not clear. In order to gain an insight of the binding 
mode of Naphthoquinones with topoisomerase I enzyme, docking analysis was 
performed. Further a pharmacophoric map of the receptor and ligand was constructed to 
establish a structure activity relationship to rationalize the design of specific scaffolds 
and thus, to understand physiochemical properties and structural parameters of the 
pharmacophore. 2D, 3D-QSAR analysis of entire Naphthoquinone derivatives was 
performed. The extreme specificity of biological activity is described by 3-D 
intermolecular forces and predicated on 3-D molecular structures. Thus in additions to 
physicochemical parameters, steric and electrostatic forces were used as descriptors for 
3D QSAR analysis40 - 43.  
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CHAPTER - II 
LITERATURE REVIEW 
1. Norma et al., (2000) studied the “Synthesis and characterization of new 
naphthoquinonic derivatives containing the pyrazole ring: pyrazolyl 
naphthoquinones. This study described the reaction of 3-aminopyrazole with 
1,2-naphthoquinone-4-sulfonic acid sodium salt  was studied in different 
aqueous media. The synthesized novel pyrazolyl naphthoquinones derivatives 
were characterized by various spectroscopic and physical methods including 2D 
NMR.44 
2. Kim et al., (2006) studied “Synthesis and evaluation of antitumor activity of 
novel 1,4- naphthoquinone derivatives”. In this study 2- or 6-substituted 5,8-
dimethoxy-l,4-naphthoquinone (DMNQ) and 5,8-dihydroxy-l,4-naphthoquinone 
(DHNQ) derivatives were synthesized, and their cytotoxic activity against 
L1210 and P388 cancer cells was examined. Their antitumor activity was also 
assessed in mice bearing S-180 cells in the peritoneal cavity. In comparison with 
the DMNQ derivatives, the DHNQ derivatives exhibited more potent 
bioactivities than the DMNQ derivatives against both L1210 and P388 cells in 
vitro and S-180 cells in vivo. The ED50 values of the DHNQ derivatives against 
P388 cells were in the range of 0.18- 1.81 pg/mL whereas those of the DMNQ 
derivatives were in the range of 0.26-40.41 pg/mL.45 
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3. Chau Tran et al., (2009) studied the “Synthesis and biological evaluation of 
halogen substituted 1, 4-naphthoquinones as potent antifungal agents”. In this 
study a series of halogen containing 1, 4-naphthoquinon derivatives were 
synthesized and all synthezied compounds were evaluated for their antifungal 
activities against C. albicans ATCC10231, C. albicans 955, T. mentagrophytes 
and M. gypseum. From the results three compounds such as 2-hydroxy-3-chloro-
1,4-naphthoquinone,  2-(N-acetyl)- acetamido-3-chloro- 1,4-napthoquinone and 
2-(N-acetyl)-acetamido-3-chloro- 1,4- napthoquinone shows potent antifungal 
activity when compared to standard  antifungal drug clotrimazole.45 
O
O
Cl
Cl
+
NH2
R
1
R
2
O
O
Cl
NH
R
1
R
2
Methanol
50-600C
 
4. Wang et al., (2012) studied the “Green Synthesis of 3-Hydroxynaphthalene-1,4-
dione Derivatives via Microwave-Assisted Three-Component Reactions in Neat 
Water”. I this study deals with a synthesis of a novel and efficient access to 2-
(argio(3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazol-4-yl) methyl)-3-
hydroxynaphthalene-1,4-dione derivatives from readily available substrates in 
neat water is described with aid of microwave irradiation. The results of this 
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study provide a green, simple and practical one-pot approach to the synthesis of 
3-hydroxynaphthalene-1,4-dione analogs in excellent yields without further 
purification46. 
 
5. Silva et al., (2013) studied the “Synthesis of 2, 3-diyne-1, 4-naphthoquinone 
derivatives and evaluation of cytotoxic activity against tumor cell lines”. This 
study described a synthesize of a series of 2, 3-diyne-1,4-naphthoquinone 
derivatives  from 2,3-dibromo- 1,4-naphthoquinone and various functionalized 
terminal alkynes using palladium-catalyzed Sonogashira cross-coupling 
reaction. The diynes were evaluated as potential cytotoxic agents against three 
tumor cell lines: human ovarian adenocarcinoma (OVCAR-8), human metastatic 
prostate cancer (PC-3M) and human bronchoalveolar lung carcinoma (NCI-
H358M). In general, they exhibited inhibitory concentrations (IC50) smaller 
than 10 μM for all three tested tumor cell lines, characterizing potent cytotoxic 
action48. 
 
6. Dumanska et al., (2013) studied “Synthesis of new fused tricyclic quinoid 
systems and studying of their biological activity in-silico”. In this study they are 
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deals with the interaction between 5-R-substituted derivatives of 1,4-
naphthoquinone and 2,3-dimethylbutadiene was carried out by Diels-Alder 
reaction. Using PASS software the biological activity of the newly designed 
compounds was established. The basic ways of modifying the synthesized 
products to increase their biological activity were developed49. 
 
7. Kulkarni et al., (2013) studied “Molecular Dynamics, Docking and QSAR 
analysis of Napthoquinone derivatives as Topoisomerase I Inhibitors”. In this 
article the docking procedure with the aim to investigate the binding 
conformations adopted by a set of 90 Naphthoquinone derivatives as 
Topoisomerase I inhibitors are done. The uses of Topo I-DNA cleavable 
complex help us to study the eventual variations in the orientation of active site 
residues, thus allowing docking structures with bulky substituents. The average 
ΔG values seen to be low in all the derivatives. The analysis of the best docked 
conformations allow us to investigate the binding mode of compounds involved 
in this study, confirming the role of some amino acids present in the active site 
as previously studied for other Topo I inhibitors50. 
8. Berghot et al., (2014) studied the “Synthesis, antioxidant and cytotoxic activities 
of novel naphthoquinone derivatives from 2, 3-dihydro-2, 3-epoxy-1, 4- 
naphthoquinone”.  In this work deals with a series of newly naphthoquinone 
derivatives were synthesized using 2, 3- dihydro-2, 3 epoxy-1, 4-
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naphthoquinone as a starting material. The 2-Hydroxy-3-(2-oxo-2-
phenylethyl)naphthalene-1, 4-dione derivative was used as building blocks for 
synthesis of different heterocycles incorporated naphthoquinone moiety. All 
synthesized compounds were evaluated as antioxidant activity by superoxide 
(NBT) free radical scavenging methods.  Among these compounds  2-(2-(3-
Hydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-1-(4- methoxy- phenyl)-3-oxo-
3-phenylpropyl)malononitrile, and 2-(2-(4-chlorophenyl)-4-phenyl-
2,10adihydro- 1H- benzo[4,5]thiazolo[3,2-a]pyrimidin-3-yl)-3-
hydroxynaphthalene- 1,4-dione produce more potent antioxidant agents than 
ascorbic acid. Moreover, the newly synthesized quinones were tested for their 
cytotoxicity by brine shrimp lethality bioassay. From the result its clearly shows 
some compounds produce significant cytotoxic activity51. 
 
9. Prachayasittikul et al., (2014) studied the “Synthesis, anticancer activity and 
qsar study of 1,4-naphthoquinone derivatives”. In this study a series of 2-
substituted amino-3-chloro-1,4-naphthoquinone derivatives were synthesized 
and evaluated against four cancer cell lines including HepG2, HuCCA-1, A549 
and MOLT-3. The most potent cytotoxic activity against the HepG2, HuCCA-1 
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and A549 cell lines was found to be macetylphenylamino- 1,4-naphthoquinone  
affording IC50 values of 4.758, 2.364 and 12.279 mM, respectively. On the 
other hand, p-acetylphenylamino-1,4-naphthoquinone exhibited the most potent 
cytotoxic activity against the MOLT-3 cell line with an IC50 of 2.118 mM. 
Quantitative structure activity relationship (QSAR) investigations provided good 
predictive performance as observed from cross validated R of 0.9177 - 0.9753 
and RMSE of 0.0614 - 0.188152. 
 
10. Susi et al., (2014) studied “The molecular docking of 1,4-naphthoquinone 
derivatives as inhibitors of polo-like kinase 1 using molegro virtual docker”. The 
aim of this study to find polo like kinase 1 inhibitor potential from 
naphthoquinone derivative through binding free energy analysis into polo like 
kinase 1. Docking process, the interaction and binding of ligands – protein was 
done and visualized using software Molegro Virtual Docking. The results 
showed no hydrogen bonding and electrostatic interaction between compound 
Naphthoquinone modified into oxime (NO11) with Plk1, but this compound 
have more steric interaction with Phe 133, Asp 194, Glu 101, Lys 82, Cys 133 
and Glu 140 of Plk1. Moldock scores of compound NO11, is -134.73 kcal/mol. 
The modified naphthoquinone compounds fits well in the active site of polo like 
kinase-1 and also interact with the residues in the active site which are important 
for their biological activity. Therefore modified naphthoquinone compounds 
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could be a putative inhibitor of plk1 and might be used as anticancer drug 
candidates53. 
 
11. Wang et al., (2015) describe the “Synthesis and biological evaluation of 
lipophilic 1,4-naphthoquinone derivatives against human cancer cell lines”. In 
this study they are synthesized a series of 1,4-naphthoquinone derivatives 
containing a 2-O-alkyl-, 3-C-alkyl- or 2/3-N-morpholinoalkyl groups evaluated 
for their anticancer activity against five human cancer cell lines in vitro. The 
cytotoxicity of these derivatives was assayed against HT-29, SW480, HepG2, 
MCF-7 and HL-60 cells by the MTT assay. Among all synthesized compounds, 
2-hydroxy-3-farnesyl-1, 4-naphthoquinone was found to be the most cytotoxic 
against these cell lines54. 
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12. Delarmelina et al., (2015) describe on “The synthesis, antitumor activity and 
docking of 2,3 (substituted)-1,4-naphthoquinone derivatives containing nitrogen, 
oxygen and sulfur”. In this study they are synthesized eleven 2,3-(substituted)-
1,4-naphthoquinone derivatives with yields ranging from 52-89%. The docking 
studies done by using auto dock vina software, topoisomer II used as target 
enzyme. These derivatives were evaluated for their cytotoxic effects on human 
lungs (H460), triple-negative breast (MDA-MB-231) and ovarian (A2780) 
cancer cell lines. Among these compound 2 Chloro-3-[(mercaptomethyl) thio] 
naphthoquinone and 2-((2-Hydroxyethyl) thio) naphthalene -1,4-dione shows 
greater in vitro antitumor activity against human lung cancer line H460 and 
compound 2-((2-Hydroxyethyl) thio) naphthalene -1,4-dione and 2-Chloro-3-
((2-hydroxyethyl) amino) naphthalene-1,4-dione shows better in vitro antitumor 
activity against triple-negative breast cancer line MDA-MB-231. The compound 
2,3-Bis[(2-hydroxyethyl)thio]naphthoquinone and 2-((2-Hydroxyethyl) thio) 
naphthalene -1,4-dione shows better in vitro antitumor activity against ovarian 
A2780 cancer cell line55. 
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13. Cemil Ibis et al., (2014) studied the “Nucleophilic substitution reactions of 1,4-
naphthoquinone and biologic properties of novel S-, S,S-, N-, and N,S-
substituted 1,4-naphthoquinone derivatives”. In this study a novel series of S-, 
S,S-, N- and N,S-substituted 1,4-naphthoquinone derivatives were synthesized 
and evaluated for their antibacterial and antifungal activity. Among the 
synthesized compounds especially 10a and 11b have been discovered as 
antibacterial or antifungal agents, and 15f is the most effective compound 
against M. luteum as potent antifungal. The structures of the novel products 
were characterized by micro analysis, UV/Vis, 1H NMR, 13C NMR, and MS. 
The electrochemical properties of some of the novel 1,4-naphthoquinone 
derivatives were also investigated by cyclic voltammetry56. 
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CHAPTER ‐ III 
3.1 AIM AND PLAN 
Aim 
The main  aim  of  this  proposed  research work  is  to  establish  the  design  and 
synthesize  a  novel  class  of  substituted  2‐  amino  3‐chloronaphthalene‐1,4‐dione 
derivatives  and    characterization  by  using    IR,  1H  NMR,  13C  NMR  and  mass 
spectroscopy.  Further  these  novel  set  of  compounds  will  be  screened  for  various 
pharmacological activities. 
Objective  
¾ The project describes the general methods of synthesis, purification and 
identification of some novel class of substituted 2- amino 3-chloronaphthalene-
1,4-dione derivatives by chromatographic & spectral methods. Since these 
compounds are reported to possess various biological activities, all of these 
compounds were screened for different activities based on the reported 
literature. 
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3.2 PLAN OF WORK 
The proposed work was planed as follows, 
¾ Design and synthesize of some novel class of substituted 2- amino 3-
chloronaphthalene-1,4-dione derivatives . 
¾ Develop the efficient methodologies for accomplishing their synthesis. 
¾ Elucidate the structure of synthesized molecule by IR, 1H NMR, 13C NMR and 
mass spectroscopy. 
¾ Perform the quantitative structure activity relationship (QSAR) of newly 
synthesized bioactive compound. 
¾ Biological evaluation of newly synthesize compound such as, 
o Anti - cancer 
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 CHAPTER - IV 
4. SCHEME OF THE WORK 
 
A series of 2-amino-3-chloro-1,4-naphthalene – 1,4-dione were synthesized via 
the nucleophilic substitution reaction of 2,3- dichloro-1,4-naphthoquinone (1) by 
appropriate secondary amines (2) in refluxing ethanol. 
 
Scheme of the work 
 
4.1. General procedure for the synthesis of title compounds 
A mixture of appropriate secondary amine (5 mmol) and 2,3- 
dichloronaphthalene -1,4-dione  (5 mmol) in absolute ethanol (20 mL) was stirred under 
reflux with stirring until completion of the reaction as monitored by TLC, Pet. Ether and 
ethyl acetate (5:5) used as solvent system and then concentrated under reduced pressure. 
Water (20 mL) was added and extracted with Ethyl acetate (30 mL). The organic layer 
was dried over anhydrous sodium sulfate, filtered and concentrated. The crude product 
was purified using silica gel column chromatography to afford the pure product. 
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Figure 4.1. Structure of title compounds 
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CHAPTER V 
5. EXPERIMENTAL SECTION 
5.1. Materials and methods 
All the chemicals were purchased from sigma Aldrich U.S.A. Analytical TLC 
was performed on Precoated sheets of silica gel G/UV-254 of 0.2mm thickness 
(Macherey-Nagel, Germany) using analytical grade solvent and visualized with iodine 
spray (10% w/w I2 in silica gel) or UV light. We also used bioinformatics tools, 
biological databases like PDB (Protein Data Bank) and software’s like Autodock and 
ACD ChemSketch. The PDB (Protein Data Bank) is the single worldwide archive of 
Structural data of Biological macromolecules, established in Brookhaven National 
Laboratories (BNL). It contains Structural information of the macromolecules 
determined by X-ray crystallographic, NMR methods etc. Auto Dock is an automated 
docking tool. It is designed to predict how small molecules, such as substrates, bind to a 
receptor of known 3D structures. Argus lab also one of the automated docking tool. 
5.2. Equipment and analytical instrument 
Melting point was determined in capillary tubes and is uncorrected. IR spectra 
were taken as KBr pellets for solids on Perkin Elmer Spectrum FT-IR. 1H NMR 
(400MHz) and 13C NMR (100 MHz) spectra were recorded in DMSO-d6 solution with 
TMS as an internal standard on Bruker instrument. Spin multiplicities are given as s 
(singlet), d (doublet), t (triplet) and m (multiplet). Coupling constant (J) is given in 
hertz. Mass spectra were recorded on a thermo Finnigan LCQ Advantage MAX 6000 
ESI spectrometer. 
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5.3.1. Synthesis of 5-((3-chloro-1,4-dioxo-1,4-dihydronaphthalen-2-yl)amino) 
pyrimidine -2,4(1H,3H)-dione (L1) 
 
A mixture of 5-aminopyrimidine-2,4dione (5-amino uracil) (5 mmol) and 2,3- 
dichloronaphthalene -1,4-dione  (5 mmol) in absolute ethanol (20 mL) was stirred under 
reflux with stirring until completion of the reaction as monitored by TLC, Pet. Ether and 
ethyl acetate (5:5) used as solvent system and then concentrated under reduced pressure. 
Water (20 mL) was added and extracted with Ethyl acetate (30 mL). The organic layer 
was dried over anhydrous sodium sulfate, filtered and concentrated. The crude product 
was purified using silica gel column chromatography to afford the pure product. 
5.3.2. Synthesis of 5-((3-chloro-1,4-dioxo-1,4-dihydronaphthalen-2-yl)amino)-1,3-
dimethylpyrimidine-2,4(1H,3H)-dione (L2) 
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A mixture of 5-amino 1,3-dimethylpyrimidine-2,4dione (5-amino 1,3-dimethyl 
uracil) (5 mmol) and 2,3- dichloronaphthalene -1,4-dione  (5 mmol) in absolute ethanol 
(20 mL) was stirred under reflux with stirring until completion of the reaction as 
monitored by TLC, Pet. Ether and ethyl acetate (5:5) used as solvent system and then 
concentrated under reduced pressure. Water (20 mL) was added and extracted with 
Ethyl acetate (30 mL). The organic layer was dried over anhydrous sodium sulfate, 
filtered and concentrated. The crude product was purified using silica gel column 
chromatography to afford the pure product. 
5.3.3. Synthesis of 2-((2H-chromen-2-yl)amino)-3-chloronaphthalene-1,4-dione 
 
A mixture of 2-amino-chromen (5 mmol) and 2,3- dichloronaphthalene -1,4-
dione  (5 mmol) in absolute ethanol (20 mL) was stirred under reflux with stirring until 
completion of the reaction as monitored by TLC, Pet. Ether and ethyl acetate (5:5) used 
as solvent system and then concentrated under reduced pressure. Water (20 mL) was 
added and extracted with Ethyl acetate (30 mL). The organic layer was dried over 
anhydrous sodium sulfate, filtered and concentrated. The crude product was purified 
using silica gel column chromatography to afford the pure product. 
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5.3.4. Synthesis of 2-chloro-3-(furan-2-ylamino)naphthalene-1,4-dione 
O
O
Cl
Cl
2,3-dichloronaphthalene-1,4-dione
+
Ethanol
RefluxOH2N
furan-2-amine
Cl
NH
O
O
O
L4
 
A mixture of 2-amino-furan (5 mmol) and 2,3- dichloronaphthalene -1,4-dione  
(5 mmol) in absolute ethanol (20 mL) was stirred under reflux with stirring until 
completion of the reaction as monitored by TLC, Pet. Ether and ethyl acetate (5:5) used 
as solvent system and then concentrated under reduced pressure. Water (20 mL) was 
added and extracted with Ethyl acetate (30 mL). The organic layer was dried over 
anhydrous sodium sulfate, filtered and concentrated. The crude product was purified 
using silica gel column chromatography to afford the pure product. 
5.3.5. Synthesis of N'-(3-chloro-1,4-dioxo-1,4-dihydronaphthalen-2-yl) isonicotino 
hydrazide 
 
A mixture of isonicotinohydrazide (5 mmol) and 2,3- dichloronaphthalene -1,4-
dione  (5 mmol) in absolute ethanol (20 mL) was stirred under reflux with stirring until 
completion of the reaction as monitored by TLC, Pet. Ether and ethyl acetate (5:5) used 
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as solvent system and then concentrated under reduced pressure. Water (20 mL) was 
added and extracted with Ethyl acetate (30 mL). The organic layer was dried over 
anhydrous sodium sulfate, filtered and concentrated. The crude product was purified 
using silica gel column chromatography to afford the pure product. 
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CHAPTER VI 
6. CHARECTERIZATION OF TITLE COMPOUNDS 
6.1. Spectral data for synthesized compound 
6.1.1. IR spectral data 
 
 
Figure 6.1. IR spectra of compound L1 
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Figure 6.2. IR spectra of compound L2 
 
 
 
Figure 6.3. IR spectra of compound L3 
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Figure 6.4. IR spectra of compound L4 
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Figure 6.5. IR spectra of compound L5 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
JKKN College of Pharmacy, Kumarapalayam.  Page 52 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.1.2. NMR spectral data 
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Figure.6.6. 1H NMR spectrum of compound L1 
 
 
Figure.6.7. 13C NMR spectrum of compound L1 
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6.1.3. Mass Spectra 
 
Figure 6.8: Mass Spectra of Compound L2 
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Figure 6.9: Mass Spectra of Compound L5 
 
 
 
 
6.2. CHARACTERIZATION OF TITLE COMPOUNDS 
 
6.2.1. 5-((3-chloro-1,4-dioxo-1,4-dihydronaphthalen-2-yl)amino)pyrimidine-
2,4(1H,3H)-dione (L1) 
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Molecular formula  : C14H8ClN3O4 
Molecular weight  : 317.68 gm 
Melting Point  : 515 – 5180C 
Appearance   : Dark Orange Solid 
IR (KBr)  :  N-H (S)-(3393), C=N (s)-(1687), C=O (Str)-(1679) ,C=C (S)- 
                                     1451, C-H (B)-(763), 678 – C-Cl (str) 
1H NMR   : 10.0 (s 1-NH), 7.92 (d, 2H), 7.88 (s 1H), 7.60 (d, 2H), 6.0 (s,  
                                       NH) 
13C NMR   : 178.3 (2 C=O quinone), 161.1 (C=O, Uracil), 150.0 (C=O,   
                                                         Uracil), 161.1, 145.02, 135.97, 135.97, 130.12, 131.34, 129.34,  
127.65, 126.80, 101.9 
Elemental Analysis : C, 52.93; H, 2.54; Cl, 11.16; N, 13.23; O, 20.15 
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6.2.2. 5-((3-chloro-1,4-dioxo-1,4-dihydronaphthalen-2-yl)amino)-1,3-dimethyl 
pyrimidine -2,4(1H,3H)-dione (L2) 
 
Molecular formula  : C16H12ClN3O4 
Molecular weight  : 345.74 gm 
Melting Point  : 525 – 5270C 
Appearance   : Dark Orange Solid 
IR (KBr)  :  N-H (S)-(3397), C=N (s)-(1697), C=O (Str)-(1664) ,C=C (S)- 
                                     1451, C-H (B)-(763), 678 – C-Cl (str) 
1H NMR   : 10.0 (s 1-NH), 7.92 (d, 2H), 7.88 (s 1H), 7.60 (d, 2H), 6.0 (s,  
                                       NH), 3.30 (t, 3H, Methyl), 3.16 (t, 3H, Methyl) 
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13C NMR   : 178.3 (2 C=O quinone), 161.1 (C=O, Uracil), 150.0 (C=O,   
                                                         Uracil), 161.1, 145.02, 135.97, 135.97, 130.12, 131.34, 129.34,  
                                      127.65, 126.80, 101.9, 36.6 (methyl carbon), 29.4 (Methyl                
Carbon) 
Elemental Analysis : C, 55.58; H, 3.50; Cl, 10.25; N, 12.15; O, 18.51 
 
 
 
 
 
 
6.2.3. 2-((2H-chromen-2-yl)amino)-3-chloronaphthalene-1,4-dione (L3) 
 
Molecular formula  : C19H12ClNO3 
Molecular weight  : 337.76 gm 
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Melting Point  : 451 - 4530C 
Appearance   : Orange Solid 
IR (KBr)  :  N-H (S)-(3397), 2785.50 (CH Str), C=O (Str)-(1600.97) ,C=C  
(Str) - 1273, C-H (B)-(863), 678 – C-Cl (str) 
1H NMR   : 7.92 (d, 2H), 7.60 (d, 2H), 7.64 (s, 1H), 7.20 (s, 1H), 6.98 (d,  
  2H), 5.98 (s, 1H), 5.88 (s, 1H), 5.51 (s, 1H) 2.0 (s, NH) 
13C NMR   : 180.09 (2 C=O quinone),126.8, 126.8, 135.0, 135.4, 130.76,  
131.02, 114.70, 156.2, 121.78, 122.4, 128.5, 120.9, 128.8, 114.2, 
157.6, 89.8                                                          
Elemental Analysis :  C, 67.56; H, 3.58; Cl, 10.50; N, 4.15; O, 14.21. 
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6.2.4. 2-chloro-3-(furan-2-ylamino)naphthalene-1,4-dione (L4) 
 
Molecular formula  : C14H8ClNO3 
Molecular weight  : 273.67 gm 
Melting Point  : 410 -4120C 
Appearance   : Green Solid 
IR (KBr)  :  N-H (S)-(3397), 2786.50 (CH Str), C=O (Str)-(1670.97) ,C=C  
(Str) - 1273, 1474 (CH2), C-H (B)-(883), 758 – C-Cl (str) 
1H NMR   : 7.92 (d, 2H), 7.60 (d, 2H), 7.88 (s, 1H), 7.00 (s, 1H), 6.68 (s, 
1H) 
2.0 (s, NH) 
13C NMR   : 178.09 (2 C=O quinone), 135.0, 135.4, 130.76, 126.8, 126.8,  
131.02, 114.70, 156.2, 143.9, 143.2, 114.2, 109.9.                                                          
Elemental Analysis : C, 61.44; H, 2.95; Cl, 12.95; N, 5.12; O, 17.54 
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6.2.5. N'-(3-chloro-1,4-dioxo-1,4-dihydronaphthalen-2-yl)isonicotinohydrazide (L5) 
 
Molecular formula  : C16H10ClN3O3 
Molecular weight  : 327.72 gm 
Melting Point  : 560 – 5620C 
Appearance   : Puff colour Solid 
IR (KBr)  : 3027 - N-H (S), 2896.50 - CH Str, 1644.97 - C=O (Str),  
1273 - C=C (Str), 1588 (NH Vibration), 1468.1 (C-H bending),  
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758 – C-Cl (str) 
1H NMR   : 8.99 (d, 2H), 8.00 (s, NH), 7.92 (d, 2H), 7.60 (d, 2H), 7.81 (d,  
  2H), 7.00 (s, 1H), 6.68 (s, 1H), 2.0 (s, NH) 
13C NMR   : 178.09 (2 C=O quinone), 135.0, 135.4, 130.76, 126.8, 126.8,  
131.02, 114.70, 156.2, 143.9, 121.71, 121.7, 149.7, 149.7                                                        
Elemental Analysis : C, 58.64; H, 3.08; Cl, 10.82; N, 12.82; O, 14.65 
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CHAPTER VII 
7. PRELIMINARY QSAR STUDIES 
Table.7.1. Physico-chemical properties of synthesized compounds 
Com 
code Structure 
Molecular 
Formula Mol weight 
Melting 
point 
Appearanc
e 
L1 C14H8ClN3O4 317.68 515 – 518
Dark 
Orange 
L2 C16H12ClN3O4 345.74 525 – 527
Dark 
Orange 
L3 C19H12ClNO3 337.76 451 - 453 
Orange 
solid 
L4 C14H8ClNO3 273.67 410 -412 
Green 
colour 
L5  
 
C16H10ClN3O3 327.72 560 – 562
Puff colour 
Colour 
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Table.7.2. Solubility data of synthesized compounds 
Compoun
d code 
Wate
r 
Aceton
e 
Chlorofor
m 
DMS
O 
Ethano
l 
Methano
l 
Ethyl 
acetat
e 
L1 - + ++ +++ + ++ ++ 
L2 - + ++ +++ + ++ ++ 
L3 - + ++ +++ + ++ ++ 
L4 - + ++ +++ + ++ ++ 
L5 - + ++ +++ ++ ++ ++ 
+++ = Freely soluble; ++ = Soluble; + = Slightly soluble; - = Insoluble 
Table7.3. QSAR studies of synthesized compounds 
Compound 
Code 
Log 
P TPSA 
N 
atoms 
n ON
N 
OHNH
N 
Violation 
N 
rotb Volume
L1 1.30 104.30 22 7 3 0 2 250.80 
L2 1.82 86.79 24 7 1 0 2 283.97 
L3 4.08 55.40 24 4 1 0 2 278.32 
L4 3.34 55.40 19 4 1 0 2 217.50 
L5 1.56 88.16 23 6 2 0 3 263.16 
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Table. 7.4. Lipinski rule for title compounds 
Compound 
code 
Molecular 
Weight 
No. of H
bond 
donor 
No. of H 
bond 
Acceptor 
TPSA 
No. of 
Rotatable 
Bond 
Log P 
L1 317.68 7 3 104.30 2 2.09 
L2 345.74 7 1 86.76 2 3.14 
L3 337.76 4 1 55.40 2 4.56 
L4 273.67 4 1 55.40 2 3.34 
L5 327.72 6 2 87.63 3 2.02 
 
Table.7.5. Drug likeness score for title compounds 
 
Compound 
Code 
GPCR 
Ligand 
Ion 
channel 
modulator
Kinase 
Inhibitor 
Nuclear 
Receptor 
ligand 
Protease 
Inhibitor 
Enzyme 
Inhibitor 
L1 -0.19 -0.35 -0.02 -0.63 0.09 0.11 
L2  0.10 -0.44 0.06 -0.22 -0.43 0.12 
L3 -0.35 -0.47 -0.24 -0.33 -0.41 0.01 
L4 -0.43 -0.80 -0.19 -0.94 -0.87 -0.11 
L5  -0.19 -0.54 0.06 -0.81 -0.28 0.06 
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CHAPTER VIII 
8. DOCKING STUDY 
8.1. Docking Studies of Synthesized Compound on Various Enzymes  
8.1.1. Introduction 
In the field of molecular modeling, docking is a method which predicts the 
preferred orientation of one molecule to second when bound to each other to form a 
stable complex and it is also key tool in structural molecular biology and computer 
assisted drug design. Docking is frequently used to predict the binding orientation of 
small molecule drug candidates to their protein targets in order to in turn predict the 
affinity and activity of the small molecule57. The small molecule, known as ligand 
usually fits within the proteins cavity which is predicted by search algorithm. These 
protein cavities become active when come in contact with any external compounds and 
are thus called as active sites. Hence docking plays an important role in the rational 
design in drugs58.  
Docking is a method which predicts the preferred orientation of one molecule to 
a second molecule when bound to each other to form a stable complex in three 
dimensional spaces. In cell biology, the function protein is a result of its interaction with 
other proteins as well as other molecule components. So if we could predict how protein 
interacts with other molecules, we could possibly inhibit the function. Thus the result of 
docking was extremely beneficial in finding drugs which are effective against particular 
disease. The knowledge of the preferred orientation in turn may be used to predict the 
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strength of association or binding affinity between two molecules using scoring 
function. 
There is much commercially available docking software each using a different 
combination of searching method and algorithm and scoring function. These are 
• GOLD (Genetic Optimization for Ligand Docking) 
• Glide 
• Drug Discovery 
• Auto dock 1.5.4 
Among these in my research work i have used auto dock software to calculate the free 
energy binding of ligand towards various target enzymes. 
  8.1.2. Autodock 1.5.4 
Autodock is a software suite to develop in Scripps Research Institute. This 
software is used for modeling flexible small molecule such as drug molecule binding to 
receptor proteins. The current version of Autodcok uses genetic algorithm for the 
conformational search and is a suitable method for the docking studies. Scripps 
Research Institute has developed a Graphical User Interface (GUI) using Python 2.5 
language, and it is called Autodock Tool (ADT). ADT is used to prepare, run and 
analyze the docking stimulation, in addition to its several features necessary for 
modeling studies.  
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8.1.4. Major steps involved in molecular docking 
Step I – Building the receptor 
In this step the 3D structure of the receptor should be downloaded from PDB 
and modified. This should include removal of water molecules from the cavity, 
stabilizing charges, filling in the missing residue, generation of side chain etc., 
according to the parameters available. After modification the receptor should be 
biologically active and stable. 
Step II – Identification of active site 
After the receptor is build, the active site within the receptor should be 
identified. The receptor may have many active sites but the one of the interest should be 
selected.  
Step III – Ligand preparation  
Ligand can be obtain from various databases like ZINC, PubChem or can be 
sketched using tools like chemsketch. While selecting the ligand, the Lipinski rule of 5 
should be applied.  The rule is very important for drug development where the 
pharmacologically active lead structure is optimized stepwise for increased activity and 
selectivity as well as drug like properties.  
 Step IV – Docking 
This is a last step, where the ligand is docked into receptor and the interaction 
are checked. The scoring function generates depending on which ligand with best fit 
was selected.  
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Molecular docking study  
In order to gain more insight on the binding mode of the compounds with 
Topoisomerase II docking studies using Auto Dock 4.0.1 were carried out. Top scoring 
molecules from the largest cluster were considered for interaction studies. The 
crystallographic structure of Topoisomerase II, which is retrieved from the RCSB 
Protein Data Bank (PDB code 3L4K) serves as docking receptor, and all the designed 
compounds are selected as ligand molecules. Before docking the screened ligands in to 
the protein active site, the protein was prepared by deleting the substrate cofactor as 
well as the crystallographically observed water molecules and then protein was defined 
for generating the grid. All molecules were drawn using ChemDraw Ultra 8.0 tool and 
energy minimized using Chem 3D Ultra 8.0 software.  
Auto Dock 4.0.1 procedure 
Automated docking was used to locate the appropriate binding orientations and 
conformations of various inhibitors into the 3L4K binding pocket. To perform the task, 
the powerful genetic algorithm method implemented in the program Auto Dock 4.0.1 
was employed. Grid maps were generated by AutoGrid program. Each grid was 
centered at the crystal structure of the corresponding 1G2A and 2GT1 separately. 
Lamarckian Genetic Algorithm was employed as the docking algorithm. The grid 
dimensions were 60 Å X 60 Å X 60 Å with points separated by 0.375 Å. For all ligands, 
random starting positions, random orientations and torsions were used. During docking, 
grid parameters were specified for x, y and z axes as 38.808, 30.946 and 42.249 
respectively. The Docking parameters Number of Genetic Algorithm (GA) runs: 25, 
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Population size: 150, Maximum number of evaluation: 2,500,000, Maximum number of 
generation: 27,000 were used for this study. The structure with the lowest binding free 
energy and the most cluster members was chosen for the optimum docking 
conformation. 
Table 8.1: Energy minimization table of Ligand and Topoisomerase II 
Interaction 
Code 
Binding 
Energy 
(Kcal/mol) 
 
Inhibition 
Constant 
Vdw. 
Desolvation 
Energy 
Intermol 
Energy 
Ligand 
efficiency 
Electrostatic 
Energy 
Total 
internal
L1 - 7.83 715.9 -8.92 -8.98 -0.38 -0.06 -0.34 
L2 -9.86 9.36 -9.15 -9.16 -0.29 -0.01 -0.44 
L3  -10.66 15.28 -11.2 -11.26 -0.44 -0.66 -0.89 
L4 -7.98 17.73 -8.45 -8.56 -0.65 -0.98 -0.32 
L5 -6.57 15.19 -7.75 -7.47 -0.29 0.1 -0.24 
Standard 
(Etoposide) 
-9.56 24.87 -10.65 10.79 -0.24 -0.75 -0.64 
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Table 8.2: Hydrogen bond and hydrophobic interaction of ligand against target enzyme 
Topoisomerase II 
Compound 
code 
No. of 
Hydrogen 
bonds formed 
Amino acid involved 
in H bond interaction
H bond 
distance 
Amino acid 
involved in vander 
waals interaction 
L1 1 Pro A: ASN828:O 2.8 
Asn 828, Ser 755, 
Asn 756, Gln 703, 
Gly 747, Gln 773. 
L2 2 
1. Pro A:TYR734:O 
2.  pro A:His735:ND1 
2.54 
2.92 
His 736, Tyr 734, 
Lys 603, Ala 733, 
Asp 809. 
L3 2 
1.proB:DC8:O5’ 
2.pro:D:DG8:O5’ 
2.80 
2.78 
Asn 828, Ser 755, 
Asn 756, Gln 703, 
Lys 603, Ala 733, 
Asp 809. 
L4 1  Pro A: GLN732 2.90 
His 736, Tyr 734, 
Lys 603, Ala 733, 
Asp 809 
L5 Nil Nil  NIL  
Asn 828, Ser 755, 
Asn 756, Gln 703, 
Lys 603, Ala 733, 
Asp 809. 
Standard 
(Etoposide) 
Nil Nil Nil 
His 736, Tyr 734, 
Lys 603, Ala 733, 
Asp 809. 
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Figure 8.1: Docking pose of Compound L1 against Topoisomerase II as Target 
Enzyme 
 
Figure 8.2: Docking pose of Compound L2 against Topoisomerase II as Target 
Enzyme 
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Figure 8.3: Docking pose of Compound L3 against Topoisomerase II as Target 
Enzyme 
 
Figure 8.4: Docking pose of Compound L4 against Topoisomerase II as Target 
Enzyme 
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Figure 8.5: Docking pose of Compound L5 against Topoisomerase II as Target 
Enzyme 
 
 
Figure 8.5: Docking pose of Standard (Etoposide) against Topoisomerase II as Target 
Enzyme 
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CHAPTER IX 
9. IN-VITRO ANTICANCER ACTIVITY 
9.1. Introduction  
Cancers are a large family of diseases which involve abnormal cell growth 
with the potential to invade or spread to other parts of the body. They form a subset of 
neoplasms. A neoplasm or tumor is a group of cells that have undergone unregulated 
growth, and will often form a mass or lump, but may be distributed diffusely. 
Six characteristics of cancer have been proposed: 
• Self-sufficiency in growth signaling 
• Insensitivity to anti-growth signals 
• Evasion of apoptosis 
• Enabling of a limitless replicative potential 
• Induction and sustainment of angiogenesis 
• Activation of metastasis and invasion of tissue. 
The progression from normal cells to cells that can form a discernible mass to 
outright cancer involves multiple steps known as malignant progression. 
The great majority of cancers, some 90–95% of cases, are due to 
environmental factors. The remaining 5–10% is due to inherited genetics. 
Environmental, as used by cancer researchers, means any cause that is not inherited 
genetically, such as lifestyle, economic and behavioral factors, and not merely 
pollution. Common environmental factors that contribute to cancer death include 
tobacco (25–30%), diet and obesity (30–35%), infections (15–20%), radiation (both 
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ionizing and non ionizing, up to 10%), stress, lack of physical activity, and 
environmental pollutants. 
9.2. Anticancer Drug Development 
Around the world, tremendous resources are being invested in prevention, 
diagnosis, and treatment of cancer. Cancer is the second leading cause of death in 
Europe and North America. Discovery and development of anticancer agents are the 
key focus of several pharmaceutical companies as well as nonprofit government and 
non-government organizations, like the National Cancer Institute (NCI) in the United 
States, the European Organization for Research and Treatment of Cancer (EORTC), 
and the British Cancer Research Campaign (CRC). 
Identification of cytotoxic compounds led the development of anticancer 
therapeutics for several decades. Advances in cancer treatment, however, continued to 
be limited by the identification of unique biochemical aspects of malignancies that 
could be exploited to selectively target tumor cells. Schwartsmann et al. noted in 1988 
that of over 600,000 compounds screened by then, less than 40 agents were routinely 
used in the clinic. The recent growth in molecular sciences and the advances in 
genomics and proteomics have generated several potential new drug targets, leading 
to changes in the paradigms of anticancer drug discovery toward molecularly targeted 
therapeutics. These shifting paradigms have not only resulted in the greater 
involvement of biological scientists in the drug discovery process but also required 
changes in the screening and clinical evaluation of drug candidates. Both small and 
large molecular compounds continue to be investigated as anticancer agents. 
The discovery and development of anticancer drugs, especially cytotoxic 
agents, differ significantly from the drug development process for any other 
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indication. The unique challenges and opportunities in working with these agents are 
reflected in each stage of the drug development process. This chapter will highlight 
the unique aspects of anticancer drug discovery and development. 
9.3. In-Vitro Anticancer Activity by SRB Assay 
In order to study the anti tumor activity of new compound, it is important to 
determine the cytotoxicity concentration of the compound. Cytotoxicity tests define 
the upper limit of the extract concentration, which is non toxic to the cell line. After 
the addition of the drug, cell death and cell viability was estimated. The result is 
confirmed by additional metabolic intervention experiment such as SRB assay. 
9.3.1. Materials Required SRB Assay 
1. Monolayer culture in log phase 
2. Drug extracts (different concentration) 
3. 0.45 filter 
4. 5mL sterile storage vials 
5. Tissue paper, Marker pen, Spirit, Cotton, and Gloves 
6. 1mL, 2mL pipettes, Micropipettes and tips 
7. Discarding Jar with 1% Hypochlorite solution 
9.3.2. SRB Assay introduction 
The sulforhodamine B (SRB) assay, which was developed in 1990, remains 
one of the most widely used methods for in vitro cytotoxicity screening. The assay 
relies on the ability of SRB to bind to protein components of cells that have been 
fixed to tissue culture plates by trichloroacetic acid (TCA). SRB is a bright-pink 
aminoxanthene dye with two sulfonic groups that bind to basic amino-acid residues 
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under mild acidic conditions, and dissociate under basic conditions. As the binding of 
SRB is stoichiometric, the amount of dye extracted from stained cells is directly 
proportional to the cell mass. 
The strong intensity of SRB staining allows the assay to be carried out in a 96-
well format showed that the assay can detect densities as low as 1,000–2,000 cells per 
well. The SRB method has proven to be practical, because after the TCA-fixed and 
SRB-stained cell monolayers are dried they can be stored indefinitely. Color extracted 
from SRB-stained cells is also stable. With its high level of sensitivity, adaptability to 
the 96-well format and endpoint stability, the SRB assay is well suited to large-scale 
screening applications, as well as research.  
This assay has been widely used for drug-toxicity testing against different 
types of cancerous and non-cancerous cell lines. Other cell-growth assays have been 
employed to assess drug efficacy against both intracellular pathogens and host cells 
simultaneously in co-cultures and it is possible to use the SRB method for this 
purpose. In addition, the SRB method has also been shown to be effective for in vitro 
testing of cancer cell sensitivity to radiation, and for the study of interactions between 
radiotherapy and chemotherapy, with sensitivity comparable to that of the standard 
clonogenic assay. 
The application of the SRB assay is limited to manual or semiautomatic 
screening due to the multiple washing and drying steps, which, at present, are not 
amenable to automation. This method nevertheless provides an efficient and sensitive 
tool for screening, especially for use in less well-equipped laboratories.  
Calculate the percentage of cell-growth inhibition using the formulae below. 
For primary screening, we use a threshold of 50% cell-growth inhibition as a cut-off 
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for compound toxicity against cell lines. However, the threshold can be varied 
according to toxicity criteria defined by the investigators. For IC50 determination, 
plot a dose–response curve between the compound concentration and percent growth 
inhibition. IC50 values can be derived using curve-fitting methods with statistical 
analysis software or IC50 calculation software. 
9.3.3. Experimental Procedure for SRB Assay 
• The cell lines were grown in RPMI 1640 medium containing 10% fetal bovine 
serum and 2 mM L-glutamine. For present screening experiment, cells were 
inoculated into 96 well microtiter plates in 100 µL at plating densities as 
shown in the study details above, depending on the doubling time of 
individual cell lines. After cell inoculation, the microtiter plates were 
incubated at 37° C, 5 % CO2, 95 % air and 100 % relative humidity for 24 h 
prior to addition of experimental drugs.  
• Experimental drugs were initially solubilize in dimethyl sulfoxide at 100 
mg/ml and diluted to 1mg/ml using water and stored frozen prior to use. At the 
time of drug addition, an aliquote of frozen concentrate (1mg/ml) was thawed 
and diluted to 100 μg/ml, 200 μg/ml, 400 μg/ml and 800 μg/ml with complete 
medium containing test article. Aliquots of 10 µl of these different drug 
dilutions were added to the appropriate micro titer wells already containing 90 
µl of medium, resulting in the required final drug concentrations i.e.10 μg/ml, 
20 μg/ml, 40 μg/ml, 80 μg/ml.  
• After compound addition, plates were incubated at standard conditions for 48 
hours and assay was terminated by the addition of cold TCA. Cells were fixed 
in situ by the gentle addition of 50 µl of cold 30 % (w/v) TCA (final 
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concentration, 10 % TCA) and incubated for 60 minutes at 4°C. The 
supernatant was discarded; the plates were washed five times with tap water 
and air dried. Sulforhodamine B (SRB) solution (50 µl) at 0.4 % (w/v) in 1 % 
acetic acid was added to each of the wells, and plates were incubated for 20 
minutes at room temperature. After staining, unbound dye was recovered and 
the residual dye was removed by washing five times with 1 % acetic acid. The 
plates were air dried. Bound stain was subsequently eluted with 10 mM trizma 
base, and the absorbance was read on an plate reader at a wavelength of 540 
nm with 690 nm reference wavelength.  
• Percent growth was calculated on a plate-by-plate basis for test wells relative 
to control wells. Percent growth was expressed as the ratio of average 
absorbance of the test well to the average absorbance of the control wells * 
100.  
• Using the six absorbance measurements [time zero (Tz), control growth (C), 
and test growth in the presence of drug at the four concentration levels (Ti)], 
the percentage growth was calculated at each of the drug concentration levels. 
Percentage growth inhibition was calculated as:  
[Ti/C] x 100 % 
• In this study Adrimycin used as standard drug. The table 9.1 shows the SRB 
assay of tested compounds against Human Breast Cancer Cell Line MCF -7. 
• The Figure 9.1 represented the drug treated Human Breast Cancer Cell Line 
MCF -7. 
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Table 9.1. The SRB Assay of tested compounds against Human Breast Cancer Cell Line MCF -7 
Code 
Human Breast  Cancer cell line  ( MCF-7 ) 
%Control Growth 
Drug concentration ( µg/ml) 
Experiment 1 Experiment 2 Experiment 3 Average Values 
10 20 40 80 10 20 40 80 10 20 40 80 10 20 40 80 
L1 66.6 57.3 48.3 44.9 72.8 90.6 71.1 9.0 103.3 81.2 58.1 42.3 80.9 76.4 59.1 32.0 
L2 55.9 70.0 49.8 31.5 87.3 102.8 55.9 15.0 90.7 68.9 60.1 25.7 78.0 80.6 55.3 24.1 
L3 46.2 36.0 32.1 7.3 83.6 36.1 41.9 20.4 85.4 61.4 33.6 20.0 71.7 44.5 35.9 15.9 
L4 60.6 60.1 60.6 75.7 107.9 96.4 89.3 80.8 118.9 88.5 38.4 71.9 95.8 81.6 62.8 76.1 
L5 42.1 52.2 44.5 20.3 78.5 104.6 81.9 44.3 110.2 64.3 57.2 36.9 76.9 73.7 61.2 33.8 
ADR -63.9 -67.2 - -52.0 -61.1 -63.0 - - -68.3 - - - - - - -58.3 
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CHAPTER X 
10. RESULT & DISCUSSION 
10.1. Result 
10.1.1. Synthetic methodology 
A series of novel class of  2 amino 3 chloro napthelene – 1,4, dione  derivatives 
were synthesized by  using 2,3- dichloronaphthalene -1,4-dione  and various secondary 
amine like 5-amino uracil (L1) , 5-amino 1,3-dimethyl uracil (L2), 2-amino-chromen 
(L3), 2-amino-furan (L4) and isonicotinohydrazide (L5) in presence of ethanol. 
10.1.2. Characterization of synthesized compounds 
¾ The purity of synthesized compounds was confirmed by melting point and TLC 
using Ethyl Acetate: Petroleum Ether (50:50) as solvent system. 
¾ The structures of synthesized compounds were confirmed by FT-IR, 1H-NMR, 
13C-NMR and Mass spectral analysis the result was correlated with the expected 
structure. 
10.1.3. Preliminary QSAR study: 
¾ The physic chemical character of title compounds were evaluated and given in 
the table 7.1. 
¾ Solubility parameters of synthesized compounds were tested, using various 
organic solvents and the result was tabulated in Table 7.2. 
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¾ The synthesized compounds were subject to Preliminary QSAR studies by 
using MOLINSPIRATION software and the results are given in the Table7.3. 
All the synthesized compounds obey Lipinski rule of 5. 
10.1.4. Docking study 
The newly designed molecules are energy minimized and the resulting 
molecules are considered for docking analysis using Auto Dock 4.0.1. Auto Dock is 
employed to study the docking molecules within active site region of 3L4K and the H-
bond interaction. Docked scores of newly designed molecules along with inhibition 
constant, Vdw. Desolvation Energy, ligand efficacy and electrostatic energy and 
hydrogen bonds are represented in Table 8.1. and table 8.2. respectively. Among the 
studied compounds, compound L3 have highest binding score (-10.66 K Cal/mol with 
one hydrogen bond) when compared with standard drugs such as Etaposide -9.56 K 
Cal/mol followed by compound L2 with score of -9.86 K Cal/mol with 2 hydrogen 
bond, compound L1 with score of -7.83 K Cal/mol with one hydrogen bond, compound 
L4 have score of –7.93 with one hydrogen bond and lastly compound L5 with score of -
6.57 K Cal/mol. The docked molecule with Topoisomerase II was visualized in 
Chimara software and the docking pose of compounds showed in figure 8.1 – 8.6. 
Docking results show that all the designed molecules have similar orientations in the 
binding pocket of Topoisomerase II.   
  
Result and Discussion 
Dept. of Pharmaceutical chemistry, JKKNCP.   
 
Page | 64
10.1.5. In vitro Anti-cancer Activity 
¾ Synthesized compounds L1, L2, L3, L4 and L5 were evaluated for anticancer 
activity by SRB assay method against Human Breast Cancer Cell Line  MCF -7. 
¾ All tested compound exhibit moderate to good percentage of growth inhibition of 
Human Breast Cancer Cell Line  MCF -7 when compared with the control drug 
Adriamycin.  
10.2. Discussion  
Quinones are ubiquitous in nature and are present in many drugs such as 
anthracyclines, daunorubicin, doxorubicin, mitomycin, mitoxantrones and saintopin, 
which are used clinically in the therapy of solid cancers.57,58. The quinone scaffold is 
presented in many currently used anticancer drugs. Particularly, substituted 
naphthoquinones are active quinone derivatives that are widely used as raw materials in 
pharmaceuticals and agrochemicals industries. A diverse array of bioactivities has been 
reported for substituted naphthoquinone derivatives to exert anticancer, antimicrobial, 
antifungal, antiviral, radical scavenging,  antiplatelet and trypanocidal activities.59-64. 
Due to the prevalence, morbidity and mortality, cancer represent significant medical, 
social, financial burden on the society. Recently, great attention has been drawn on the 
research for new anticancer drugs in order to improve survival rates and wellbeing.  
The mechanism of action of naphthoquinones involves oxidants and electrophile 
properties influenced by their chemical structure.65 There are two important 
mechanisms of quinone cytotoxicity: stimulation of oxidative stress and alkylation of 
cellular nucleophiles, which encompass a large range of biomolecules. Reactive oxygen 
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species (ROS) may react directly with DNA, lipids and proteins, leading to cell 
damage66,67 and shunting electrons toward oxygen, a futile pathway for reduction 
equivalents otherwise used for cytochrome P450 reductase-dependent reactions. 
Cellular damage can also occur through the alkylation of crucial proteins and nucleic 
acids.68-71 Besides the mechanism of ROS production, cytotoxic effect of clinically used 
quinone-based anticancer drugs are closely related to an inhibition of DNA 
topoisomerase II enzyme.72,73 The DNA topoisomerase II is an essential enzyme 
required for DNA replication, chromosome condensation and chromosome 
segregation.74. DNA unwinding process is a crucial step in which the coils of double 
stranded DNA needs to be uncoiled thereby allowing further processes of DNA 
replication.75 In silico approaches play an important role in drug design and 
development. Quantitative structural activity relationship (QSAR) is a computational 
method for correlating chemical structures of compounds with their respective 
biological activities.76,77 Furthermore, QSAR studies could provide crucial 
pharmacokinetic information such as absorption, distribution, metabolism and  
excretion78,79. which are important parameters in drug design and development. 
Here, a series of 2-amino-3-chloro substituted naphthoquinone derivatives (five) were 
synthesized using the nucleophilic displacement reaction of 2,3-dichloro-1,4-
naphthoquinone by amines and subsequently investigated for their cytotoxic activity 
against for human breast cancer cell line MCF-7. The resulting experimental data were 
consequently used for QSAR analysis. In order to elucidate the effect of 2-substituted 
amino group on the 1,4-naphthoquinone scaffold, an additional set of 5 structurally 
modified compounds were virtually constructed. The structures of the synthesized 
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compounds were studied using Autodock software against Topoisomerease II as target 
enzymes. The docking results showed that Compounds L3, L2, L4, and L1 were found 
to have significant binding score against target enzyme Topoisomerase compared to 
standard drug Etaposide. Compounds  L3 and L2  were  allowed only  15.9 and 24.1 % 
cell growth at the conc. of 80 µg / ml respectively where as other compounds has 
showed  25 – 78 % cell growth  when compared to Standard  Adrimycin . These results 
indicated that the studied compounds exhibit the In vitro anticancer activity against the 
Breast cancer cell line MCF-7. Novel anticancer agents such as compound L2 and L3 
exhibited the most potent cytotoxic activity against MCF – 7 cell lines. The study 
shown that the effects of substituent’s at the 2-amino position on the naphthoquinone 
core structure and its corresponding influence on the cytotoxic activity. 
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CHAPTER XI 
11. CONCLUSION 
¾ The present study deals with designing of some novel substituted 2 -amino 3-
chloro naphthalene – 1,4 dione derivatives on the basis reaction between 2,3- 
dichloronaphthalene -1,4-dione  and various secondary amine like 5-amino 
uracil (L1) , 5-amino 1,3-dimethyl uracil (L2), 2-amino-chromen (L3), 2-amino-
furan (L4) and isonicotinohydrazide (L5) in presence of ethanol. 
¾ The synthesized compounds were characterized by IR, 1H NMR, 13C NMR, 
Mass spectrometry and elementary analysis. 
¾ Preliminary QSAR study was carried out for the synthesized compounds. All the 
compounds obeyed the Lipnski rule of 5. 
¾ Solubility characters of synthesized compounds were carried out by using 
various solvents. The tested compounds are freely soluble in DMSO, soluble in 
chloroform and methanol, slightly soluble in acetone, ethyl acetate and ethanol 
and insoluble in water. 
¾ The structures of the synthesized compounds were studied using Autodock 
software against Topoisomerease II as a target enzymes. The docking results 
showed that Compounds L3, L2, L4, and L1 were found to have significant 
binding score against target enzyme Topoisomerase compared to standard drug 
Etaposide.  
¾ Compounds  L3 andL2  were  allowed only  15.9 and 24.1 % cell growth at the 
conc. of 80 µg / ml respectively where as other compounds has showed  25 – 78 
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% cell growth  when compared to Standard  Adrimycin . This results indicated 
that the studied compounds exhibit the Invitro Anti- cancer activity against the 
Breast cancer cell line MCF-7. 
¾ A series of 1,4-naphthoquinone derivatives were synthesized and investigated 
for their cytotoxic activity against MCF – 7 cell lines. Novel anticancer agents 
such as compound L2 and L3 exhibited the most potent cytotoxic activity 
against MCF – 7 cell lines. 
¾ The study may be concluding that the effects of substituents at the 2-amino 
position on the naphthoquinone core structure and its corresponding influence 
on the cytotoxic activity. 
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